Source - RNS
RNS Number : 2748L
Sphere Medical Holding plc
30 September 2016
 

                                                                                                           30 September 2016

 

Sphere Medical Holding plc

("Sphere Medical" or the "Company")

       

Sphere Medical achieves CE marking for Proxima 4

 

~ Preparation for commercial launch in Europe well underway ~

 

Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, is today pleased to announce that all four components of its Proxima 4 device have received CE mark registration, enabling market launch in Europe.

 

Proxima 4 is the new generation of Sphere's innovative patient-connected device used for measuring blood gases, electrolytes and metabolites. It incorporates a number of significant enhancements over the currently available product, Proxima 3. Based on market demand and usability studies, these include the addition of glucose and sodium to the panel of analytes, and a number of important usability improvements.

 

The Company is continuing with preparations for the European commercial launch of Proxima 4, including readying the supply chain, and it remains on track to achieve the launch later this year.

 

Wolfgang Rencken, the Company's Chief Executive Officer, commented: "With the CE-marking of Proxima 4 we have achieved one of our strategic goals for 2016. This will mean that the benefits of Proxima will be available to a much larger group of patients. We now look forward to its commercial launch later this year and building sales momentum."

 

Professor Mike Grocott, consultant in Critical Care Medicine at the University Hospital Southampton, commented: "The recent time and motion study we conducted at University Hospital Southampton clearly highlighted the workflow benefits of using Proxima on critically ill, unstable patients. We look forward to the launch of Proxima 4 and the opportunity to use this device on a larger patient group within the ICU."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

- Ends -

 

For further information, please contact:

 

Sphere Medical Holding plc

Tel: +44 (0)1223 875 222

Dr Wolfgang Rencken, Chief Executive Officer


Richard Wright, Chief Financial Officer




Panmure Gordon

Tel: +44 (0) 20 7886 2500

Freddy Crossley (Corporate Finance)


Duncan Monteith (Corporate Finance)


Tom Salvesen (Corporate Broking)




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott

[email protected]

Chris Gardner


Ivar Milligan


Hendrik Thys


 

 

Notes for Editors

 

About Sphere Medical (AIM: SPHR.L)

 

Sphere Medical is an innovative point-of-care medical device company. Its Proxima platform measures blood gases, electrolytes and metabolites at the patient's bedside and aims to improve patient care and reduce health system costs. The device is currently sold directly to the critical care market via Sphere Medical's sales force in the UK, Germany, The Netherlands and Belgium. For further information, please visit www.spheremedical.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMMGZLZLMGVZZ

Related Charts

Sphere Medical Holding (SPHR)

-0.25p (-2.44%)
delayed 18:15PM